011000.KS
GeneOne Life Science, Inc.
KSC · Healthcare · Biotechnology · KR
KRW 2,670.00
+400.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 18.0B | 23.9B | 35.7B | 40.2B | 48.7B |
| Cost of Revenue | 32.3B | 45.4B | 46.6B | 48.0B | 39.4B |
| Gross Profit | (14.3B) | (21.4B) | (10.9B) | (7.8B) | 9.3B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 1.9B | 3.6B | 7.0B | 12.1B |
| SG&A Expense | 7.2B | 7.7B | 6.0B | 7.5B | 7.4B |
| General & Admin Expense | 1.4B | 1.7B | 1.9B | 2.1B | 1.4B |
| Selling & Marketing Expense | 5.9B | 6.0B | 4.1B | 5.5B | 6.0B |
| Other Expenses | 13.0B | 11.4B | 22.6B | 26.0B | 29.8B |
| Total Operating Expenses | 21.4B | 21.0B | 32.2B | 40.6B | 49.4B |
| Cost and Expenses | 53.7B | 66.4B | 78.8B | 88.6B | 88.8B |
| Operating Income (EBIT) | (35.7B) | (42.4B) | (43.0B) | (48.4B) | (40.1B) |
| Non-Operating | |||||
| Interest Income | 208.3M | 186.6M | 125.2M | 518.7M | 6.2B |
| Interest Expense | 1.9B | 2.4B | 2.2B | 1.2B | 7.3B |
| Net Interest Income | (1.7B) | (2.2B) | (2.0B) | (661.0M) | (1.1B) |
| Other Non-Op Income/Expense | (5.4B) | (5.2B) | (5.7B) | (29.3B) | 2.0B |
| Non-Operating Income (excl Interest) | (7.9B) | — | 3.6B | 28.1B | (9.3B) |
| EBT (Pre-Tax Income) | (41.1B) | (47.6B) | (48.8B) | (77.7B) | (38.1B) |
| Income Tax Expense | 64.6M | 87.4M | (216.2M) | 113.4M | 95.8M |
| Bottom Line | |||||
| Net Income | (41.2B) | (47.7B) | (48.5B) | (77.8B) | (38.2B) |
| Earnings from Cont. Ops | (41.2B) | (47.7B) | (48.5B) | (77.8B) | (38.2B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (41.2B) | (47.7B) | (48.5B) | (77.8B) | (38.2B) |
| Per Share | |||||
| Basic EPS | (₩11,848) | (₩13,951) | (₩15,220) | (₩25,006) | (₩12,309) |
| Diluted EPS | (₩11,848) | (₩13,951) | (₩15,220) | (₩25,006) | (₩12,309) |
| Revenue Per Share | ₩1,037 | ₩7,006 | ₩11,239 | ₩12,927 | ₩15,718 |
| Shares | |||||
| Basic Shares Outstanding | 17.4M | 3.4M | 3.2M | 3.1M | 3.1M |
| Diluted Shares Outstanding | 17.4M | 3.4M | 3.2M | 3.1M | 3.1M |
| Profitability Metrics | |||||
| EBITDA | (26.2B) | (28.6B) | (28.6B) | (63.7B) | (25.3B) |
| D&A | 13.8B | 18.2B | 18.0B | 12.8B | 5.4B |
| EBIT | (40.1B) | (46.8B) | (46.6B) | (76.5B) | (30.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026